Monoclonal antibodies that bind human CD161
US11459389B2 · kind B2 · utility
2Cited by
7References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 24, 2020 |
| Grant date | Oct 4, 2022 |
| Priority date | — |
| Expiry date | Oct 6, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD161 an inhibit the interaction between CD161 and CLEC2D, and the use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.